Prophylactic administration of L-arginine improves the intestinal barrier function after mesenteric ischaemia

R Schleiffer, F Raul

Abstract

Background—Ischaemia/reperfusion (I/R) of the intestine causes mucosal injury associated with a high death rate in rats. 

Aim—To investigate whether nitric oxide (NO) might be implicated in the recovery of the intestinal mucosa after ischaemic insult.

Methods—Wistar rats were subjected to mesenteric artery occlusion for 90 minutes. The animals were given either L-arginine, the substrate of NO synthase, or molsidomine, a NO donor. The controls received casein hydrolysate. The compounds were administered by gavage 19, 16, and 1-5 hours before ischaemia. Mucosal barrier permeability and cGMP content were determined 24 hours after ischaemia.

Results—Survival after I/R was 50% in the control group. Animals treated with L-arginine or molsidomine exhibited a higher survival rate (70% and 83% respectively). Mucosal barrier permeability was decreased in rats receiving L-arginine or molsidomine compared with controls (4.0 (0.9) and 2.6 (0.6) vs 11.2 (1.6) 14C-PEG pmol/segment, p < 0.05). Increased cGMP content was seen in the mucosa of the L-arginine group.

Conclusion—The findings suggest that pretreatment with L-arginine or molsidomine ameliorates survival after intestinal I/R and improves mucosal barrier function.

(Gut; 1996; 39: 194–198)

Keywords: nitric oxide, ischaemia/reperfusion, intestine, mucosal barrier permeability.

It has clearly been shown in animals that morphological and functional injury of the intestinal mucosa occurs during ischaemia and is exacerbated after re-establishment of tissue perfusion. This injury includes mucosal barrier disruption leading to increased mucosal and vascular permeability, bacterial translocation, and a high death rate. It has been proposed that most of the mucosal injury resulting from ischaemia/reperfusion (I/R) is mediated by production and release of reactive oxygen derived free radicals when hypoxic tissues are reoxygenated during reperfusion. It is consistent with the effect of nitric oxide (NO) to protect the gastrointestinal tract from I/R injury. As NO activates guanylate cyclase and increases cGMP formation, which mainly account for the NO effects, we determined intestinal mucosal cGMP content. As an index of intestinal function, we measured hydrolyase activities in the mucosa.

Methods

Animals

Male Wistar rats weighing 360–430 g (Laboratoires Janvier, France) and fed a standard diet (A04 from UAR, Villemoisson/Orge, France) were used. The animals were deprived of food 24 hours before surgery and during the whole experiment but were allowed free access to drinking water. The animals were assigned to one of the four groups: (1) casein-I/R (control) rats were given casein hydrolysate (0.8 g/kg wt), (2) L-arginine-I/R rats were given L-arginine by gavage (100 mg/kg wt) at 19, 16, and 1.5 h before reperfusion, (3) casein hydrolysate-L-arginine rats were given casein hydrolysate (0.8 g/kg wt) and L-arginine by gavage (100 mg/kg wt) at 19, 16, and 1.5 h before reperfusion, (4) molsidomine-I/R rats were given molsidomine by gavage (100 mg/kg wt) at 19, 16, and 1.5 h before reperfusion.
given L-arginine, the substrate of NO (0.8 g/kg wt), (3) molsidomine-I/R rats were given molsidomine, a NO donor (12 mg/kg wt) at a dose expected to result in similar haemodynamic effects to L-arginine (R Henning, personal communication), and (4) L-NAME-I/R rats were given NO-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO biosynthesis (50 mg/kg wt).

An additional group of sham operated rats were given casein hydrolysate but were not subjected to ischaemia.

Compounds were administered by gavage 19, 16, and 1-5 hours before sham surgery or ischaemia.

Ischaemia procedure

The rats were anaesthetised by intraperitoneal injection of ketamine (Imalgene 1000, 150 μl/100 g wt). After induction of anaesthesia, the rats underwent midline laparotomy and the intestine was exposed. Inferior mesenteric artery was isolated near its aortic origin and occluded with an arterial bulldog clamp. Collateral blood flow interruption was achieved by ligating the right colonic artery and the jejunal arcades just proximal to the point of the mesenteric artery occlusion as described by Megson et al.22 In the sham operated rats, the mesenteric artery and collateral vessels were isolated in a similar fashion but not occluded. The intestine was replaced into the peritoneal cavity for the duration of ischaemic period. The animals were placed under a heating lamp to maintain body temperature at 37°C. After 90 minutes, the arterial clamp was removed and the abdomen closed. The animals were then placed in plastic cages and mortality observed for each group.

Determination of mucosal permeability

Permeability of the mucosal barrier was assessed by measuring the lumen to blood fluxes of 14C-PEG using a modification of the technique described by Winne and Görg.23 Briefly, 24 hours after the beginning of intestinal reperfusion the rats were anaesthetised by intraperitoneal injection of ethyl carbamate (1 ml/100 g wt). A catheter was inserted into the left jugular vein. The intestine was then exposed after a midline laparotomy. The in situ length of the jejunum was measured using a thread placed along its curved axis. The jejunum was cross sectioned in its middle and a 5 cm length segment just above the section was ligated at the two extremities with a thread. The rat was then placed into a box, which was kept at 37°C and dampened by circulating water. The exposed intestinal segment was covered with saline soaked gauze to prevent desiccation. Heparin (600 U/kg wt) was then injected through the jugular vein. The mesenteric vein draining the isolated intestinal segment was cannulated (Polyethylene Biotrol 0-960-58 mm). To collect only the venous effluent was allowed to drain freely and was collected at intervals of two minutes into 2 ml calibrated tubes. The blood loss was compensated by jugular infusion of fresh heparinised rat blood. After stabilisation of the mesenteric venous flow rate the isolated intestinal segment was intraluminally injected with 0-5 ml of Krebs-Ringer solution containing 14C-PEG (for composition see below). The blood samples were centrifuged and the plasma 14C-PEG activity quantified by liquid scintillation counting. In all rats the time course of plasma 14C-PEG concentration showed a plateau within six to eight minutes after the beginning of blood collection (data not shown). For each two minute time period, mucosal permeability was calculated based on the mesenteric venous flow rate and plasma 14C-PEG concentration. For comparisons, 14C-PEG permeability was calculated for the integrated first 10 minute time period. The values were expressed in pmol/segment.

Venous flow rate was determined volumetrically for each two minute time interval.

Determination of mucosal hydrolyase activities and cGMP content

Before permeability measurement, a 20 cm intestinal segment, just below to the mid jejunooileum section, was resected. Immediately after resection, the segment was flushed with ice cold NaCl 0.9% and the mucosa scraped off with a glass slide. The tissue was then separated into two moieties, weighed, placed in a plastic tube, immediately frozen in liquid hydrogen, and stored at −70°C until biochemical determinations.

After mucosal homogenisation in mannitol (50 mmol/l) and 2 mmol/l TRIS (pH 7.1), sucrase activity was determined according to the method of Dahlqvist,24 and aminopeptidase activity using L-alanine-p-nitroanilide as substrate.25 For cGMP determination, the mucosa was homogenised in 1 ml of HCl (0.1 N) and centrifuged at 10 000 g for 10 minutes at 4°C. The supernatants were stored at −70°C until cGMP assay.26 27

Chemicals

14C-PEG was purchased from Amersham (Buckinghamshire, UK). The Krebs-Ringer solution contained (in mmol/l) 116 NaCl, 6 KCl, 25 NaHCO3, 1.8 CaCl2, 1.2 NaH2PO4, and 27.7 glucose, with osmolality of 300 mosm/l, and 67 μCi/l of 14C-PEG. Casein hydrolysate, L-arginine, and NO-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO biosynthesis, were obtained from Sigma. The nitrovasodilator molsidomine, which generates NO, was supplied from Cassella AG (Frankfurt, Germany). Compounds given by gavage were dissolved in distilled water immediately before use and were given in a volume of 5 ml.

Statistics

All numerical data were reported as mean
Figure 1: Effect of pretreatment with casein hydrolysate (Cas), L-arginine (L-arg), and molsidomine (Mol) on survival rate of rats subjected to ischaemia/reperfusion.

Figure 2: Effect of pretreatment with casein hydrolysate (Cas), L-arginine (L-arg), and molsidomine (Mol) on mesenteric venous blood flow in rats subjected to ischaemia/reperfusion. Each value represents the mean (SEM) of five to eight animals. Comparison to Cas* p<0.05. Value of sham operated group was 0.27 (0.05) ml/min, n=4.

Figure 3: Effect of pretreatment with casein hydrolysate (Cas), L-arginine (L-arg), and molsidomine (Mol) on intestinal barrier permeability (as measured by $^{14}$C-PEG absorption for the integrated first 10 minute time period) in rats subjected to ischaemia/reperfusion. Each value represents the mean (SEM) of five to eight animals. Comparison to Cas* p<0.05. Value of sham operated group was 2.07 (0.40) pmol/segment, n=4.

(SEM) values. Statistical comparisons were performed using ANOVA followed by Student's t test and Neuman-Keuls test, with values of p<0.05 accepted as significant.

Results

Mortality
All animals (five of five) survived in the sham operated group. Survival of the animals in the casein-I/R group was 50% (eight of 16) versus 67% (six of nine) in the L-arginine and 83% (five of six) in the molsidomine-I/R groups (Fig 1). All animals (six of six) in the L-NAME-I/R group died between six to 24 hours after the onset of reperfusion.

Mesenteric venous blood flow
Baseline mesenteric venous blood flow rates (VBFR) in the L-arginine-I/R and molsidomine-I/R groups were higher compared with casein-I/R group (Fig 2). VBFR values in the L-arginine-I/R and molsidomine-I/R groups were not different from that obtained in the sham group (0.27 (0.05) ml/min, n=4).

Intestinal barrier permeability
The intestinal barrier permeability, as measured by $^{14}$C-PEG absorption, for the three groups is shown in Figure 3. Animals pretreated with L-arginine and molsidomine had a lesser amount of $^{14}$C-PEG absorption compared with animals pretreated with casein hydrolysate. $^{14}$C-PEG absorption in the intestine from sham operated animals was 2.07 (0.40) pmol/segment (n=4).

Mucosal hydrolase activities
The Table shows the mucosal activities of sucrase and aminopeptidase. There was no significant difference between the three groups of animals indicating that mucosal hydrolase activities were not modified by the various treatments 24 hours after I/R.

Mucosal cGMP content
Figure 4 illustrates the mucosal content of cGMP. In the L-arginine-I/R group, the mucosal cGMP content was significantly higher than in casein-I/R and molsidomine-I/R groups.

Discussion
These data show that enteral pretreatment with L-arginine, the substrate of NO, or molsidomine, a NO donor, improved survival and accelerated the recovery of the intestinal barrier function of the I/R injured mucosa. We present evidence that NO is responsible for these effects. This hypothesis is further supported by the fact that pretreatment with L-NAME, the well known inhibitor of NO biosynthesis, increased mortality (in this study) and exacerbated mucosal damages occurring after intestinal I/R.16

<table>
<thead>
<tr>
<th>Group</th>
<th>Sucrase (mU/g mucosa)</th>
<th>Aminopeptidase (mU/g mucosa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein hydrolysate</td>
<td>469 (80)</td>
<td>526 (74)</td>
</tr>
<tr>
<td>L-arginine</td>
<td>419 (128)</td>
<td>538 (107)</td>
</tr>
<tr>
<td>Molsidomine</td>
<td>434 (72)</td>
<td>638 (175)</td>
</tr>
</tbody>
</table>

TABLE 1  Sucrase and aminopeptidase activities of intestinal mucosa after 24 hours of I/R in rats pretreated either with casein hydrolysate, L-arginine or molsidomine. Each value represents the mean (SEM) of five to eight animals.
Figure 4: Effect of pretreatment with casein hydrolysate (Cas), L-arginine (L-arg), and molsidomine (MoI) on intestinal mucosal cGMP content in rats subjected to ischemia/reperfusion. Each value represents the mean (SEM) of five to eight animals. Comparison to L-arg**: p<0.01.

Our results are in agreement with those reported by other investigators who have explored the protective effect of NO. Intravenous infusion of exogenous sources of NO (NO gas in solution and sodium nitroprusside, SNP) improved survival of the cat subjected to I/R.28 Inhibition of NO biosynthesis in the rat has been reported to exacerbate the damage to the intestine during endotoxic shock18 and PAF treatment.19 In addition, inhibition of NO biosynthesis during reperfusion increased the rise in I/R induced intestinal permeability in the cat.4 Inversely, L-arginine, the precursor of NO, protects the intestine from postischaemic injury by decreasing mucosal and microvascular barrier dysfunction.4 Perfusion of NO donors SIN-1, CAS754, and SNP reduced I/R induced mucosal barrier dysfunction in the cat.17 Arginine supplemented diet improves survival in gut derived sepsis and peritonitis in the mouse29 and the rat.30 Finally, in a recent study, we have shown that enteral administration of L-arginine to rats before intestinal I/R accelerated morphological and functional recovery of the injured mucosa in the small intestine.16

The mechanisms underlying the morphological and functional recovery of the injured intestinal mucosa after I/R are complex and remain unknown. Reduction in intestinal blood flow during reperfusion of the postischaemic intestine has been implicated as a contributing factor to I/R induced mucosal injury.2 13 17 31 In this study, there was an increase in mesenteric venous blood flow in L-arginine- and molsidomine-I/R animals compared with casein-I/R animals. It is therefore conceivable that the beneficial effect of pretreatment with L-arginine and molsidomine on the recovery of normal mucosal permeability was a result of the ability of these two compounds to prevent the reduction in mucosal blood flow associated with reperfusion of the postischaemic intestine. These data and those reporting that NO increased mesenteric blood flow4 32 34 support the concept that provision of exogenous NO before I/R may have beneficial properties in mucosal recovery from injury via preventing the reduction in intestinal mucosal blood flow induced by I/R. Therefore, the I/R induced mucosal injury may be in part a result of decreased NO activities.

NO is known to activate the soluble guanylate cyclase leading to accumulation of cGMP in the tissues.30 cGMP mediates further intracellular signal transduction and results in activation of protein kinases and phosphorylases, which leads to vascular smooth muscle relaxation accounting for vasodilatation.35 These data showing that cGMP content in mucosa is increased in L-arginine-I/R animals, indicate that production of NO is increased by pretreatment of L-arginine. This further supports the notion that local release of NO in the intestinal mucosa might be involved in the recovery of normal intestinal permeability.17 36

Molsidomine, once absorbed, is converted enzymatically to SIN-1,37 which then releases NO spontaneously.38 Previous reports have shown that the vasodilator effects of molsidomine in vivo are mimicked in vitro by relaxing actions of SIN-1.39 The latter effects have been attributed to the formation of NO and are mediated by stimulation of guanylate cyclase in vascular smooth muscle cells and hence increasing cGMP values.39 The results of this study indicate that mucosal cGMP content in molsidomine-I/R animals was not increased after 24 hours of I/R. The mechanisms by which molsidomine supports the effects observed in our study remain unclear. However, as intestinal absorption of molsidomine, biotransformation of molsidomine to active metabolites, NO and cGMP production from SIN-1 occur rapidly,40 41 it cannot be excluded that the improved mucosal permeability and intestinal blood flow observed in molsidomine treated animals might be mediated through the NO-cGMP pathway.

NO can be generated from L-arginine by two isoforms of the NO synthases (NOS): the constitutive NOS (cNOS), constantly producing small amount of NO and the inducible NOS (iNOS), which generates large quantities of NO in various stimulated cells.42 The cNOS is Ca2+ and calmodulin dependent whereas iNOS is Ca2+ and calmodulin independent.43 To evaluate the potential contribution of the two NOS isoforms to the rise in epithelial permeability induced by I/R, Kanvar and colleagues36 quantitated the Ca2+ dependent and independent NOS activity in the injured mucosa of cat small intestine after I/R. Their results show that Ca2+ dependent NOS activity was reduced by 50% three and four hours of reperfusion, whereas Ca2+ independent NOS activity was undetectable. These data suggest that mucosal dysfunction may be attributed to the inhibition of cNOS activity rather to iNOS.

In a study performed under the same experimental conditions, we have shown that rats pretreated with L-arginine exhibited by four hours of reperfusion a better morphological recovery of the intestinal mucosa and higher hydrolase activities than controls receiving casein hydrolysate.16 These data showed that by 24 hours of reperfusion, sucrase and...
aminopeptidase activities were similar in mucosa from casein, L-arginine, and molsidomine pretreated animals. This finding suggest that mucosal hydrolysis activities recover faster than mucosal permeability after I/R.

These data show that exogenous sources of NO (L-arginine and molsidomine) given enterally before ischaemia improved survival and intestinal mucosal barrier function. We speculate that increasing NO formation or provision of exogenous NO may exert a beneficial effect by improving intestinal recovery from ischaemic insult.

The authors would like to thank the expert technical assistance of M Galluser, A Nichini, and E Laurent, R Henning of Casella AG (Frankfurt, Germany) for the generous supply of molsidomine, and Dr B Lutz-Bucher (CNRS URA 1446, Strasbourg, France) for measurement of cGMP content in mucosa.